-
Oil prices dip, most stocks rise on lingering Iran peace hopes
-
Tim Cook's time as Apple chief marked by profit absent awe
-
Mitchell, Harden shine as Cavs down Raptors for 2-0 series lead
-
El Salvador's missing thousands buried by official indifference
-
Trump's Fed chair pick to face lawmakers at key confirmation hearing
-
PGA Tour to scrap Hawaii opening events from 2027
-
Amazon invests another $5 bn in Anthropic
-
Israel PM vows 'harsh action' against soldier vandalising Jesus statue in Lebanon
-
Wembanyama wins NBA defensive player of the year
-
'The Devil Wears Prada 2' stars reunite for glamorous premiere
-
El Salvador holds mass trial of nearly 500 alleged gang members
-
Apple's Tim Cook to step down as CEO in September
-
West Ham's draw at Palace relegates Wolves, piles pressure on Spurs
-
Canadian tourist killed in Mexico archaeological site shooting
-
Wolves relegated from Premier League
-
Oil jumps on Hormuz tensions, stocks mostly retreat
-
Colombian environmental activist honored amid threats and exile
-
Gun battle traps more than 200 tourists at Rio viewpoint
-
Alcaraz may skip French Open rather than rush injury comeback
-
Top US court to hear case of Catholic schools excluded from state funding
-
Trump Fed chair pick to vow interest rate independence at key hearing
-
EU to host Taliban officials for talks on deporting Afghans
-
Blue Origin probing rocket's failure to deliver satellite
-
Pope blasts 'exploitation' as he wraps up tour of Angola
-
Wembanyama 'changing the game as we speak', says Nowitzki
-
Singer D4vd charged with murder after teen's body found in Tesla
-
Swiss football club turn down Kanye West concert approach
-
Leicester fairytale turns sour as relegation to third tier looms
-
Pope Leo blasts 'exploitation' as he wrap up tour of resource-rich Angola
-
Varma ton revives Mumbai's IPL hopes with win over Gujarat
-
Formula One makes rule changes after drivers' criticism
-
Singer D4vd charged with murder over teen's body found in Tesla
-
UK PM denies misleading MPs, says officials hid Mandelson info
-
Tit-for-tat blockades once again cripple traffic in Hormuz
-
Cafu says 2026 World Cup is perfect time for Brazil to win again
-
Erdogan vows new measures after deadly Turkey school shootings
-
Rose to take charge at Bournemouth after Iraola exit
-
Olympic status a massive 'boost' for squash says European champion Crouin
-
Kenyan double-double as Korir, Lokedi defend Boston Marathon crowns
-
Whale stranded on German coast swims off, gets stuck again
-
Iran pulling Hormuz 'lever' to maximum in US standoff
-
Argentine film and theater great Luis Brandoni dies at 86
-
French Open sensation Boisson returns to action after 'most difficult' spell
-
Desmond Morris: from 'Naked Ape' to watching 'Big Brother'
-
Rosenior says Chelsea owners supportive despite slump
-
Oil jumps on Hormuz tensions, stocks retreat
-
Romania legend Hagi eyes 'winning every game' on return as coach
-
Rana stars as Bangladesh down New Zealand to level ODI series at 1-1
-
Real Madrid coach Arbeloa launches stout defence of Mbappe
-
Pope Leo blasts 'exploitation' on visit to resource-rich Angola
Lifeloc Unveils SpinDetect(TM) Centrifugal Drug Analyzer at First Customer Demonstrations
WHEAT RIDGE, CO / ACCESS Newswire / August 25, 2025 / Lifeloc Technologies, Inc. (OTCID:LCTC), a U.S. leader in portable alcohol and drug testing solutions, unveiled its new SpinDetect™ Centrifugal Drug Analyzer during live demonstrations at the International Association of Chiefs of Police Impaired Driving and Traffic Safety Conference held in Chicago, August 4-6, 2025.

The SpinDetect™ system brings lab-grade analytical chemistry onto a compact, automated disk platform that can be run with minimal user interaction. At the conference, law enforcement officials and toxicologists saw firsthand how the system processes oral fluid samples with results displayed in under 15 minutes.
Dr. Curtis Stumpf, Senior Scientist at Lifeloc, led the demonstrations. "It is exciting to showcase how far we've taken this technology-from benchtop chemistry to a streamlined system that runs automatically once the sample is added," said Dr. Stumpf.

Lifeloc has named the new product the SpinDetect™ Centrifugal Drug Analyzer, reflecting its foundation in the licensed SpinDx™ microfluidic technology from Sandia Corporation. The prototype kit, demonstration in progress, and prototype disk design are shown in the following photographs.
"Our prototype looks like a miniature chemical plant on a disk," said Dr. Wayne Willkomm, President and CEO of Lifeloc. "There's a section for mixing, a section for reaction, and a section for separation and measurement-all working together to indicate the presence of targeted drugs. It is a truly compact, self-contained analytical system."

Key Product Features
Validated Capability: SpinDetect™ Centrifugal Drug Analyzer has been tested in Lifeloc's laboratory against definitive LCMS methods using human saliva samples, detecting substances including delta-9-THC at approximately 10 ng/ml, as well as cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines.
Automated Workflow: Once the sample is introduced, the pre-loaded, shelf-stable test disk performs the analysis without user intervention.
Platform Potential: The modular design supports single-analyte tests (such as THC) as well as expanded drug panels under development as well as analysis of samples beyond oral fluid.
We are also beginning beta testing of our SpinDetectTM Centrifugal Drug Analyzer oral fluid testing system utilizing the delta-9-THC only. An agreement for beta testing is in place, and the test logistics are being finalized. The initial product release is projected to be a device with a disk that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject's oral fluid, followed by a disk for a panel of other drugs. Commercial launch of our first SpinDetectTM Centrifugal Drug Analyzer application is projected to occur in 2026. Lifeloc is preparing for a phased rollout of the SpinDetect™ system, beginning with THC detection disks, followed by additional drug panels and samples collected from blood and breath. Following the release of our SpinDetectTM Centrifugal Drug Analyzer oral fluid testing system, we expect to accelerate development of combining our LX9 breathalyzer with the THC SpinDetectTM Centrifugal Drug Analyzer, to produce our roadside marijuana breathalyzer system. The current pace of development may require additional financing to complete.
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTCID: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.
SpinDetectTM is a trademark of Lifeloc Technologies, Inc.
SpinDx™ is a trademark of Sandia Corporation.
Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
SOURCE: Lifeloc Technologies, Inc.
View the original press release on ACCESS Newswire
A.Jones--AMWN